Electronic Acknowledgement Receipt

EFS ID:	10315150
Application Number:	10552314
International Application Number:	
Confirmation Number:	1865
Title of Invention:	Stabilising formulation for immunoglobulin g compositions in liquid form and in lyophilised form
First Named Inventor/Applicant Name:	Annie Bardat
Customer Number:	02292
Filer:	Leonard Richard Svensson/William Gorman
Filer Authorized By:	Leonard Richard Svensson
Attorney Docket Number:	0040-0158PUS1
Receipt Date:	15-JUN-2011
Filing Date:	05-SEP-2006
Time Stamp:	21:50:15
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	$1920
RAM confirmation Number	8343
Deposit Account	022448
Authorized User	
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:	
Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)	
Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)	

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Continued Examination (RCE)	20110615RCE00400158PUS1.pdf	63358 b2f32b2319d8ca55fbc15b202b1755b3da2dc599	no	1

Warnings:

This is not a USPTO supplied RCE SB30 form.

Information:

| 2 | Transmittal Letter | 20110615Transmittal00400158PUS1.pdf | 56333
 3f5178d85c5c21fb25475448cb478f08acc6a35 | no | 1 |

Warnings:

Information:

| 3 | | 20110615Amendment00400158PUS1.pdf | 434638 <br> d658d197fbcc76944aa678c902dd360c5bbc34ac | yes | 9 |

Multipart Description/PDF files in .zip description		
Document Description	**Start**	**End**
Amendment After Final	1	1
Claims	2	3
Applicant Arguments/Remarks Made in an Amendment	4	9

Warnings:

Information:

| 4 | | 20110615IDS00400158PUS1.pdf | 219521 <br> c78febd4a47736e983153bf503e1d6682c377c36 | yes | 4 |

Multipart Description/PDF files in .zip description		
Document Description	**Start**	**End**
Transmittal Letter	1	2
Information Disclosure Statement (IDS) Form (SB08)	3	4

Warnings:

Information:

| 5 | Foreign Reference | WO9704801A1.pdf | 2376374
 0f06d3f159d6b588f0a4a0eb7d1940fb9669e0e1 | no | 49 |

Warnings:					
Information:					
6	Foreign Reference	WO02092632A1.pdf	735835 cb67c0b1e98a4dfb9e75cb28e061ca7dc3d4f	no	16
Warnings:					
Information:					
7	Foreign Reference	WO02013860A1.pdf	2024994 4c32ccfa0030dbfc46a44df3b96b6542f26a33c	no	45
Warnings:					
Information:					
8	Foreign Reference	JP61191622AandAbstract.pdf	300911 e4e9997a959133eddcca78b36bfaf72d3cc0b8609	no	6
Warnings:					
Information:					
9	Foreign Reference	EP0196761A2.pdf	575477 666ef8c86ddbb6137c0c8b2c8c2f023b87102 7bef	no	17
Warnings:					
Information:					
10	Foreign Reference	JP5025058AandAbstract.pdf	249087 52a3393fc1c373b98cf54c34bc9bc98b8e6944 20	no	5
Warnings:					
Information:					
11	Foreign Reference	EP0597101A1.pdf	344379 bb5c855a2f07fb0f3275ff31326ccf00f96a015	no	6
Warnings:					
Information:					
12	Foreign Reference	JP63088197AandAbstract.pdf	369106 63f3d95e2f79b18ea4bd62cb9f4bfcd05dbef79ca9e	no	7
Warnings:					
Information:					
13	Foreign Reference	WO9844948A2.pdf	1795667 42df026dce48b63342d0f922da9365c3205 3c0323	no	35
Warnings:					
Information:					
14	Foreign Reference	JP11510170TandAbstract.pdf	1796846 12eb2f0b1f8f775d568f7afc7081fbf164f28379	no	70

Warnings:					
Information:					
15	Foreign Reference	EP1314437A1.pdf	1148000 6ca1e2195cc62ed7e0710a4789f1d818ee84ebe	no	28
Warnings:					
Information:					
16	Non Patent Literature	PikalM_Biopharm_1990_vol3_n9_p26_p30.pdf	573767 7e43a8b4acec5d074099c0fe25dce417ec186c2e	no	5
Warnings:					
Information:					
17	Non Patent Literature	Arakawa_PharmRes_1991_8_3_285.pdf	1425791 33b1e0ad26a9b59512b9862306fbea1e629e2e7d	no	7
Warnings:					
Information:					
18	Non Patent Literature	OsterbergT_PharmRes_1997_14_7_892.pdf	678273 7c29cf385bbaba2543ce6aed435d5db2d8921a9e	no	7
Warnings:					
Information:					
19	Non Patent Literature	GuoW_Biomacromolecules_2002_vol3_n4_p846_p849.pdf	399698 5f7f3f4002c795e282718a858608864cb211161c	no	4
Warnings:					
Information:					
20	Non Patent Literature	CohnEJ_JAmChemSoc_1946_68_459.pdf	1048397 4100a393c00c5d65829ec083dfab1d70c3e79cf	no	17
Warnings:					
Information:					
21	Non Patent Literature	KistlerP_VoxSang_1962_vol7_p414_p424.pdf	410673 6dbcb01d367ac706b7776247ffa7bc8a2d9f5a4d1	no	11
Warnings:					
Information:					
22	Non Patent Literature	SteinbuchM_RevFrEtudClinBiol_1969_14_10_1054_1058.pdf	311568 792f3a421c6b44b194ca04911178fd135f1e4799e	no	5
Warnings:					
Information:					
23	Non Patent Literature	FernandesPM_VoxSang_1980_vol39_p101_p112.pdf	559723 1c90bc26291ca1a38781bc2387e13fb5aacf728b	no	12

Warnings:					
Information:					
24	Non Patent Literature	LevineHL_JParenterSciTechnol_1991_45_3_160_165.pdf	883878 4cb7edfd94061504531384cef676c1d44c7caa20	no	6
Warnings:					
Information:					
25	Non Patent Literature	Pharmacopee_Europeenne.pdf	330384 bad3c4472e8a866ead5b22ca5f778291e82325d4	no	2
Warnings:					
Information:					
26	Non Patent Literature	BleekerWK_Blood_2000_95_1856.pdf	525222 1528a1f29cd9a6b96c166b65632c79461717cf	no	6
Warnings:					
Information:					
27	Non Patent Literature	ChidwickK1999.pdf	546020 7fc3e243b8e77ea4aed4d33f0805b64ccb45c793d	no	6
Warnings:					
Information:					
28	Extension of Time	20110615EOT00400158PUS1.pdf	56991 9c6b7b70f1b29d395bbe06faea8d642fbc1b64f3	no	1
Warnings:					
Information:					
29	Fee Worksheet (SB06)	20110615FeeTransmittal00400158PUS1.pdf	65919 24b196a8aedabe32de3bbd767decac1a88f54cc0	no	1
Warnings:					
Information:					
30	Non Patent Literature	JP9500894TandAbstract.pdf	331768 3c95d6b64eeb41fbdec676a47053f8a0ed2df8f	no	16
Warnings:					
Information:					
31	Fee Worksheet (SB06)	fee-info.pdf	32105 e67f740ab451f804012d241b03989eb15228f75fb	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	20670703		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111
If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371
If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office
If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.